Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
← catalyst calendarNCT04443010 · readout ≤ 73 d
Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
226estimated
Sites
1
Country
Switzerland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-20 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2020-06-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma
Interventions
- Drug: Onfekafusp alfa — also filed as L19TNF
- Drug: Temozolomide — also filed as TMZ
Primary outcomes
what the primary-completion date above is the date OFFor Phase 1: DLT
measured For Cohort 1 and Cohort 2 from Day 1 to Day 28 of the maintenance cycle; for Cohort 3, 4 and 5 from Day 1 to Day 42 of the chemoradiotherapy.
For Phase 2: Overall Survival
measured From beginning of treatment to 52 weeks
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed